FDA approves Ambelvist for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity

Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

Earlier this year, Joe Rogan, host of “The Joe Rogan Experience” podcast, sent a text to President Donald Trump.

June 18, 2026

FDA clears a way for dramatic reduction in animal toxicology studies in cancer

FDA has issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for some cancer pharmaceuticals.

June 18, 2026

Vol.52 No.24

By Claire Marie Porter

Drugs & Targets

FDA accepts sBLA for atezolizumab for patients with stage 3 dMMR colon cancer

FDA has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq) for the treatment of patients with stage 3 colon cancer with deficient deoxyribonucleic acid mismatch repair.

June 18, 2026

Vol.52 No.24

Drugs & Targets

FDA warns providers about shortage of breast biopsy needles

FDA is warning providers about the interruptions in the supply of stereotactic breast biopsy needles because of recent supplier issues. The manufacturing disruption in supply of these devices is expected to impact patient care and may require adjustments to the clinical management of patients indicated to undergo a breast biopsy.

June 18, 2026

Vol.52 No.24

Drugs & Targets

FDA expands sunscreen options for the first time in 20 years

FDA added bemotrizinol to the list of permitted sunscreen active ingredients, marking the first new active ingredient added to the over-the-counter sunscreen monograph since the late 1990s.

June 12, 2026

Vol.52 No.23

Drugs & Targets

FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm

FDA approved Decnupaz (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval is supported by data from the phase I/II CADENZA trial, a global study evaluating the safety and efficacy of Decnupaz for BPDCN.

June 05, 2026

Vol.52 No.22

FDA approves Ambelvist for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity

YOU MAY BE INTERESTED IN

Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

FDA clears a way for dramatic reduction in animal toxicology studies in cancer

FDA accepts sBLA for atezolizumab for patients with stage 3 dMMR colon cancer

FDA warns providers about shortage of breast biopsy needles

FDA expands sunscreen options for the first time in 20 years

FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves Ambelvist for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity

YOU MAY BE INTERESTED IN

Is psilocybin heading to a cancer clinic near you?Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

FDA clears a way for dramatic reduction in animal toxicology studies in cancer

FDA accepts sBLA for atezolizumab for patients with stage 3 dMMR colon cancer

FDA warns providers about shortage of breast biopsy needles

FDA expands sunscreen options for the first time in 20 years

FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm

Never miss an issue!

Login

Is psilocybin heading to a cancer clinic near you?
Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research